The Anti-Diabetes Drugs market in Southeast Asia has been growing steadily over the years, driven by a combination of factors such as changing lifestyles, increasing urbanization, and rising disposable incomes.
Customer preferences: Customers in Southeast Asia are increasingly becoming health-conscious and are taking proactive measures to prevent and manage chronic diseases such as diabetes. As a result, there is a growing demand for anti-diabetes drugs in the region. Additionally, there is a preference for generic drugs due to their lower costs.
Trends in the market: Indonesia is the largest market for anti-diabetes drugs in Southeast Asia, followed by Thailand and the Philippines. The market is dominated by big pharmaceutical companies, with local players also having a significant presence. There is a trend towards the development of new and innovative drugs, with a focus on improving efficacy and reducing side effects. Additionally, there is a growing interest in alternative therapies such as traditional medicine and natural remedies.
Local special circumstances: The prevalence of diabetes in Southeast Asia is high, with the region having one of the highest rates of diabetes in the world. This is due to a combination of factors such as changing diets, sedentary lifestyles, and genetic predisposition. Additionally, there are challenges in accessing healthcare in certain parts of the region, which can impact the availability and affordability of anti-diabetes drugs.
Underlying macroeconomic factors: The Southeast Asian region has been experiencing strong economic growth over the years, which has led to rising disposable incomes and an increase in healthcare spending. Additionally, the region has a large and growing population, which presents a significant market opportunity for pharmaceutical companies. However, there are also challenges such as regulatory barriers and intellectual property issues that can impact the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
